ICL

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on: 
Tuesday, March 5, 2024

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points: 
  • Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
  • In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
  • In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
  • "With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, February 26, 2024

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

Tellurian Reports 2023 Financial Results and Driftwood LNG Progress

Retrieved on: 
Friday, February 23, 2024

Tellurian Inc. (Tellurian or the Company) (NYSE American: TELL) reported its full year 2023 financial results today.

Key Points: 
  • Tellurian Inc. (Tellurian or the Company) (NYSE American: TELL) reported its full year 2023 financial results today.
  • During 2023, Tellurian took significant steps to advance the Driftwood LNG project, having driven over 14,000 piles at site and making progress on concrete foundations for critical equipment thus de-risking site construction.
  • Subsequent to year end, Tellurian amended its senior secured notes and senior convertible notes to provide financial flexibility.
  • As disclosed in our financial statements, we have made significant progress in executing our plans to alleviate substantial doubt.”

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

REHOVOT, Israel, March 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Key Points: 
  • Collaboration with Colors Farm and Ben Gurion University: Evogene partnered to pioneer crustacean gene editing technology aimed at enhancing crustacean traits.
  • EU Grant for Ag-Seed Division: Evogene secured a €1.2 million EU grant to develop oil-seed crops with enhanced CO2 assimilation and drought tolerance.
  • In the fourth quarter of 2023, general and administrative expenses were approximately $1.2 million, down from about $1.7 million in the same period the previous year.
  • This increase in net loss during the fourth quarter of 2023 is primarily attributed to other income received in 2022, as mentioned above.

Verde appoints João Paulo Frez as Chief Revenue Officer

Retrieved on: 
Wednesday, February 7, 2024

SINGAPORE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce the appointment of João Paulo Frez as Chief Revenue Officer (“CRO”).

Key Points: 
  • SINGAPORE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce the appointment of João Paulo Frez as Chief Revenue Officer (“CRO”).
  • Until February 2024, Mr. Frez served as the Senior Commercial Director for Brazil at ICL, a leading global specialty minerals company.
  • “Mr Frez stands out as one of Brazil's most accomplished senior executives in specialty fertilizer sales.
  • After a year serving as Business Unit Director at ICL, Mr. Frez was promoted to the role of Senior Commercial Director.

Global Innovators in St. Louis Pitching the Future of High-Tech Farms

Retrieved on: 
Tuesday, February 6, 2024

The area also hosts the headquarters of national organizations for the farmers who raise those crops, including NCGA , and USB .

Key Points: 
  • The area also hosts the headquarters of national organizations for the farmers who raise those crops, including NCGA , and USB .
  • Like in the ABC-TV reality program ‘Shark Tank,’ the best innovations will get feedback, support and maybe even investment from the ReACH companies present.
  • (Denmark)
    Andes generates carbon credits by partnering with farmers who apply microorganisms on agricultural fields which convert CO2 into stable minerals.
  • This innovation boosts yields and sustainability simultaneously, redefining the future of sustainable and productive agriculture.

STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision

Retrieved on: 
Tuesday, January 23, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240123947715/en/
    STAAR Surgical and SharpeVision will collaborate on marketing and education activities to elevate awareness of EVO ICL and significantly increase availability of the lenses to all qualified patients in SharpeVision clinics.
  • STAAR Surgical will also provide additional practice development and clinical support.
  • “We are pleased to announce SharpeVision as a new partner under our U.S. Highway 93 go-to-market program initiated in October 2023.
  • Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery.

STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023

Retrieved on: 
Monday, January 8, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.
  • Preliminary net sales were approximately $76.5 million for the fourth quarter and approximately $322.5 million for fiscal 2023.
  • Operating margin is expected to be approximately 5% for the fourth quarter and fiscal 2023.
  • “Fiscal 2023 was a year of positive market share gains, sales growth and continued profitability for STAAR.

Lilian Zhou Appointed to STAAR Surgical Board of Directors

Retrieved on: 
Monday, December 4, 2023

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.
  • “We welcome Lilian Zhou as a new member to our Board of Directors.
  • Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • Lilian Zhou brings more than two decades of capital markets and investment experience to STAAR.

STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)

Retrieved on: 
Wednesday, November 15, 2023

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023.
  • Management will participate in a Fireside Chat on Thursday, November 16, 2023, at 6 a.m. PT / 8 a.m. CT.
  • The Fireside chat will we be webcast live at the link here .
  • In-person attendance at the conference is by invitation from the sponsoring brokerage firm, Stephens, only.